Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 15
2016 31
2017 44
2018 44
2019 57
2020 54
2021 39
2022 37
2023 32
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB, Neogi T. Vargas-Santos AB, et al. Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055. Epub 2017 Apr 26. Am J Kidney Dis. 2017. PMID: 28456346 Free PMC article.
Febuxostat-Induced Toxic Epidermal Necrolysis.
Han P, Hu L. Han P, et al. Am J Ther. 2022 Nov-Dec 01;29(6):e710-e712. doi: 10.1097/MJT.0000000000001256. Epub 2020 Oct 1. Am J Ther. 2022. PMID: 33021532 No abstract available.
Febuxostat cardiovascular safety revisited.
Onuora S. Onuora S. Nat Rev Rheumatol. 2021 Jan;17(1):3. doi: 10.1038/s41584-020-00547-1. Nat Rev Rheumatol. 2021. PMID: 33219346 No abstract available.
Safety update: febuxostat and CVD.
[No authors listed] [No authors listed] Drug Ther Bull. 2023 Jul;61(7):102. doi: 10.1136/dtb.2023.000029. Epub 2023 Jun 15. Drug Ther Bull. 2023. PMID: 37321803
320 results